{"hands_on_practices": [{"introduction": "The initial characterization of an adrenal incidentaloma relies heavily on its appearance on non-contrast and contrast-enhanced imaging. The dynamic behavior of a lesion following contrast administration provides crucial diagnostic clues about its vascularity and composition. This exercise provides direct practice in applying the principles of contrast washout, a quantitative method used to differentiate benign adrenal adenomas from potentially malignant or other non-adenoma lesions. [@problem_id:4623325]", "problem": "A $52$-year-old patient undergoing evaluation for an incidentally discovered adrenal mass has Computed Tomography (CT) attenuation measurements reported in Hounsfield units (HU) at three time points: unenhanced $8$ HU, portal venous phase $78$ HU, and $15$-minute delayed phase $34$ HU. From first principles, define enhancement and washout in terms of changes in attenuation across phases, and derive expressions for the absolute washout and the relative washout as dimensionless fractions based on these definitions. Using well-tested clinical thresholds used in the evaluation of adrenal incidentalomas, classify the lesion as lipid-rich adenoma versus not meeting adenoma washout criteria. Let the classification variable $c$ be encoded numerically, where $c=1$ indicates adenoma and $c=0$ otherwise. Compute the two washout fractions and $c$ from the given data. Express both washout values as decimals, rounded to four significant figures. Provide the final answer as a row matrix $\\left(\\text{absolute washout}, \\text{relative washout}, c\\right)$.", "solution": "The problem statement is evaluated as valid, as it is scientifically grounded in the principles of diagnostic radiology, well-posed with sufficient data for a unique solution, and objective in its language and required analysis.\n\nWe begin by defining the variables provided in the problem. Let $U$, $PV$, and $D$ represent the radiodensity measurements, in Hounsfield units (HU), of the adrenal mass during the unenhanced, portal venous, and $15$-minute delayed phases of a Computed Tomography (CT) scan, respectively.\nThe given values are:\n$U = 8$\n$PV = 78$\n$D = 34$\n\nThe task requires defining enhancement and washout from first principles.\n\n**Enhancement** is the increase in a tissue's radiodensity following the administration of an intravenous contrast agent. The magnitude of enhancement, $\\Delta_{enh}$, at the portal venous phase is the difference between the attenuation in this phase and the baseline unenhanced attenuation.\n$$ \\Delta_{enh} = PV - U $$\n\n**Washout** refers to the subsequent decrease in radiodensity as the contrast agent is cleared from the tissue over time. The rate of washout is a critical diagnostic feature for adrenal masses. Benign adrenal adenomas characteristically exhibit rapid enhancement followed by rapid washout, whereas malignant lesions (like metastases) or pheochromocytomas typically show slower washout. This difference is quantified using washout fractions.\n\nThe **Absolute Washout** fraction, denoted $W_{abs}$, is defined as the decrease in attenuation from the peak enhancement phase ($PV$) to the delayed phase ($D$), normalized by the magnitude of the initial enhancement ($\\Delta_{enh}$). This provides a measure of washout relative to how much the lesion enhanced in the first place. The expression is:\n$$ W_{abs} = \\frac{PV - D}{PV - U} $$\n\nThe **Relative Washout** fraction, denoted $W_{rel}$, is defined as the decrease in attenuation from the peak phase ($PV$) to the delayed phase ($D$), normalized by the attenuation value of the peak phase itself. This measures washout relative to the total density of the enhanced lesion, not just the enhanced component. The expression is:\n$$ W_{rel} = \\frac{PV - D}{PV} $$\n\nNext, we must classify the lesion based on well-tested clinical thresholds. The primary imaging characteristic of a lipid-rich adenoma is low attenuation on unenhanced CT, typically defined as $U \\le 10$ HU. The given value of $U=8$ HU already strongly indicates a lipid-rich adenoma.\n\nThe problem, however, requires classification based on washout criteria. For a lesion with $U > 10$ HU (a lipid-poor adenoma), or for confirmation, washout analysis is performed. A lesion is classified as a benign adenoma if its absolute washout, $W_{abs}$, is greater than or equal to $0.60$ (or $60\\%$). We define the classification variable $c$ according to this rule:\n$$ c = \\begin{cases} 1 & \\text{if } W_{abs} \\ge 0.60 \\\\ 0 & \\text{if } W_{abs} < 0.60 \\end{cases} $$\nA commonly used secondary criterion, particularly when an unenhanced scan is unavailable, is a relative washout $W_{rel} \\ge 0.40$ (or $40\\%$).\n\nWe proceed to calculate the values of $W_{abs}$, $W_{rel}$, and $c$ using the provided data: $U=8$, $PV=78$, and $D=34$.\n\nFirst, we compute the absolute washout:\n$$ W_{abs} = \\frac{78 - 34}{78 - 8} = \\frac{44}{70} = \\frac{22}{35} \\approx 0.6285714... $$\nRounding to four significant figures as requested, we obtain:\n$$ W_{abs} \\approx 0.6286 $$\n\nNext, we compute the relative washout:\n$$ W_{rel} = \\frac{78 - 34}{78} = \\frac{44}{78} = \\frac{22}{39} \\approx 0.5641025... $$\nRounding to four significant figures, we obtain:\n$$ W_{rel} \\approx 0.5641 $$\n\nFinally, we determine the classification variable $c$ by applying the threshold for absolute washout:\nSince $W_{abs} \\approx 0.6286$, we compare this value to the threshold of $0.60$.\n$$ 0.6286 \\ge 0.60 $$\nThis inequality is true. Therefore, the lesion meets the washout criteria for a benign adenoma, and the classification variable is $c=1$. This result is consistent with the finding from the unenhanced attenuation ($U = 8 \\le 10$) and the relative washout criterion ($W_{rel} \\approx 0.5641 \\ge 0.40$), all of which point to the same diagnosis.\n\nThe final answer consists of the computed values for absolute washout, relative washout, and the classification variable $c$.\n$W_{abs} = 0.6286$\n$W_{rel} = 0.5641$\n$c = 1$\nThese are to be presented as a row matrix.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.6286 & 0.5641 & 1\n\\end{pmatrix}\n}\n$$", "id": "4623325"}, {"introduction": "Once an adrenal mass is identified, a key step is to determine if it is hormonally active, an evaluation guided by the patient's clinical signs. For patients with hypertension, screening for primary aldosteronism is a priority, as it is a common and treatable cause of secondary hypertension. This practice problem focuses on the cornerstone of this screening process: the calculation and interpretation of the Aldosterone-to-Renin Ratio (ARR), connecting fundamental physiology to a critical diagnostic decision. [@problem_id:4623380]", "problem": "A $49$-year-old patient with long-standing resistant hypertension (uncontrolled blood pressure on three antihypertensive classes, including a diuretic) is found to have a unilateral adrenal incidentaloma on computed tomography (CT). The mass measures $2.2$ cm with homogeneous, lipid-rich characteristics. The patient has a history of episodic muscle weakness and documented hypokalemia. In preparation for biochemical evaluation, mineralocorticoid receptor antagonists and other interfering agents were withdrawn for appropriate washout periods, antihypertensive therapy was transitioned to non-interfering agents (verapamil sustained release, hydralazine, and doxazosin), dietary sodium intake was liberalized, and serum potassium was corrected to normal before testing. Morning blood sampling was performed after $2$ hours of upright posture followed by $10$ minutes seated rest.\n\nThe measured Plasma Aldosterone Concentration (PAC) is $18$ ng/dL and the Plasma Renin Activity (PRA) is $0.2$ ng/mL/h. Using the definition of the Aldosterone-to-Renin Ratio (ARR) as the ratio of PAC to PRA when PAC is in ng/dL and PRA is in ng/mL/h, compute the ARR as a pure number (no units). Then, based on established screening practice for primary aldosteronism in the evaluation of an adrenal incidentaloma, determine whether this value is consistent with a positive screen in a patient with resistant hypertension and a history of hypokalemia. Round your ARR to three significant figures. Express only the ARR in the final answer box as a pure number with no units.", "solution": "The evaluation of an adrenal incidentaloma in a patient with resistant hypertension and hypokalemia must include biochemical screening for autonomous aldosterone secretion (primary aldosteronism), because autonomous aldosterone secretion is characterized by inappropriately elevated aldosterone production with suppressed renin due to negative feedback on the juxtaglomerular apparatus. The Aldosterone-to-Renin Ratio (ARR) is a screening tool grounded in this physiology: elevated Plasma Aldosterone Concentration (PAC) with suppressed Plasma Renin Activity (PRA) produces a high ratio.\n\nFoundational principles and definitions:\n- In the renin-angiotensin-aldosterone system, autonomous aldosterone secretion suppresses renin via extracellular volume expansion and sodium retention.\n- The Aldosterone-to-Renin Ratio (ARR) is defined, for screening purposes, as\n$$\n\\text{ARR} = \\frac{\\text{PAC}}{\\text{PRA}}\n$$\nwhen $\\text{PAC}$ is expressed in ng/dL and $\\text{PRA}$ in ng/mL/h.\n- A well-tested clinical practice, supported by endocrine and hypertension society guidelines, uses a commonly adopted decision threshold on the order of $30$ for $\\text{ARR}$ (with $\\text{PAC} \\geq 15$ ng/dL) in these units to indicate a positive screen, warranting confirmatory testing, provided that confounders (medications, posture, sodium and potassium status) are addressed.\n\nGiven data:\n- $\\text{PAC} = 18$ ng/dL.\n- $\\text{PRA} = 0.2$ ng/mL/h.\n- Sampling conditions were standardized, interfering medications were held, and hypokalemia was corrected before testing to minimize false results.\n\nComputation:\nUsing the definition,\n$$\n\\text{ARR} = \\frac{18}{0.2} = 90.\n$$\nRounding to three significant figures gives $90.0$.\n\nInterpretation in context:\n- The $\\text{ARR}$ of $90.0$ exceeds the commonly adopted screening threshold of $30$ (in ng/dL per ng/mL/h) and the $\\text{PAC}$ is $\\geq 15$ ng/dL, supporting a positive screening result for primary aldosteronism.\n- The clinical context of resistant hypertension and a history of hypokalemia further increases the pretest probability of primary aldosteronism. Notably, hypokalemia can suppress aldosterone secretion and yield false negatives; therefore, a clearly elevated ARR despite correction of potassium (and under standardized conditions) is particularly compelling.\n- Next steps, outside the scope of the requested calculation, would typically include confirmatory testing (for example, isotonic saline infusion test, oral sodium loading test, fludrocortisone suppression test, or captopril challenge), followed by lateralization with adrenal vein sampling if primary aldosteronism is confirmed, especially in the setting of an adrenal incidentaloma.\n\nTherefore, the computed ARR is $90.0$, which is consistent with a positive screen in this clinical context.", "answer": "$$\\boxed{90.0}$$", "id": "4623380"}, {"introduction": "Effective clinical practice requires synthesizing information from multiple sources—imaging, biochemical tests, and patient history—to form a coherent and safe diagnostic strategy. This is especially true when evaluating an adrenal mass with features suspicious for a pheochromocytoma, where a misstep can have severe consequences. This final exercise challenges you to integrate ambiguous imaging and laboratory data to construct a prioritized diagnostic plan, reinforcing the cardinal rule of adrenal evaluation: first, rule out pheochromocytoma. [@problem_id:4623296]", "problem": "A $52$-year-old individual undergoes abdominal Computed Tomography (CT) for nephrolithiasis follow-up and is found to have an incidentally discovered left adrenal mass measuring $3.2$ cm in maximal diameter. On unenhanced CT, the lesion demonstrates an attenuation of $35$ Hounsfield Units (HU). Subsequent Magnetic Resonance Imaging (MRI) shows striking hyperintensity on T2-weighted sequences with internal heterogeneity. The patient has mild, labile hypertension without hypokalemia, episodic palpitations, and a recent history of starting a serotonin-norepinephrine reuptake inhibitor for depression. Initial outpatient laboratory assays demonstrate plasma free normetanephrine at $1.4$ times the upper limit of normal, with metanephrine within reference range; the sample was drawn in a seated position shortly after a stressful commute. There is no known extra-adrenal malignancy.\n\nUsing fundamental definitions of radiological signal generation and endocrine tumor physiology, interpret these findings and select the most appropriate prioritized diagnostic plan.\n\nYou may assume the following foundational bases:\n- On CT, attenuation in HU correlates with the linear X-ray attenuation coefficient; lipid-rich tissue lowers attenuation, and adrenal lipid-rich adenomas typically exhibit unenhanced attenuation <10 HU, whereas lipid-poor adenomas and many non-adenomas often show attenuation >10 HU.\n- On MRI, tissues with longer transverse relaxation time $T_2$ exhibit higher signal intensity on T2-weighted sequences; catecholamine-producing tumors such as pheochromocytoma often display marked T2 hyperintensity due to high water content, cystic change, and vascularity.\n- Catecholamine-producing tumors convert catecholamines to metanephrines via catechol-O-methyltransferase; tumor secretion is autonomous. Borderline elevations of plasma metanephrines may arise from stress, posture, or medications. Pharmacologic alpha-$2$ adrenergic agonism (clonidine) suppresses sympathetic neuronal release but not tumor production of catecholamines, thereby normalizing neurogenic elevations but not tumor-derived elevations.\n\nWhich option best prioritizes the next steps?\n\nA. Suspect pheochromocytoma based on imaging and attenuation; repeat catecholamine testing under optimal pre-analytic conditions (supine plasma free metanephrines after $20$–$30$ minutes of rest or $24$-hour urinary fractionated metanephrines) and, if borderline elevation persists, perform a clonidine suppression test targeting plasma normetanephrine. Concurrently screen for autonomous cortisol secretion with a $1$ mg overnight dexamethasone suppression test. Defer adrenal biopsy and contrast washout characterization until biochemical exclusion or confirmation of pheochromocytoma. If biochemical confirmation occurs, arrange preoperative alpha-adrenergic blockade and functional imaging such as iodine-$123$ metaiodobenzylguanidine (MIBG) or fluorine-$18$ fluorodopa positron emission tomography (PET).\n\nB. Proceed directly to percutaneous adrenal biopsy to differentiate malignancy versus adenoma; pre-procedural alpha-adrenergic blockade is unnecessary because metanephrines are only borderline.\n\nC. Classify the lesion as a lipid-poor adenoma and perform immediate contrast-enhanced adrenal washout CT to establish adenoma versus non-adenoma without further catecholamine testing, as imaging is decisive.\n\nD. Order immediate functional imaging with gallium-$68$ DOTATATE or fluorine-$18$ fluorodeoxyglucose PET to stage disease, and defer cortisol and aldosterone testing to avoid diagnostic delays, as functional imaging will clarify diagnosis.\n\nE. Begin beta-adrenergic blockade alone for symptomatic control and schedule elective adrenalectomy based on the MRI “light-bulb bright” appearance, forgoing further biochemical testing because MRI is sufficiently specific.", "solution": "The interpretation must start from radiologic physics and endocrine tumor biology.\n\nRadiologic physics and CT attenuation: The CT attenuation in Hounsfield Units (HU) is a linear transformation of the measured X-ray attenuation coefficient relative to water and air. Lipid-rich adrenal adenomas have intracellular lipid that reduces attenuation such that unenhanced values are typically <10 HU. An unenhanced attenuation of $35$ HU is not compatible with a lipid-rich adenoma and is more consistent with either a lipid-poor adenoma, pheochromocytoma, metastasis, or adrenocortical carcinoma. Therefore, the unenhanced attenuation $35$ HU increases suspicion for a non-lipid-rich entity.\n\nMRI T2 signal: On MRI, T2-weighted images accentuate signal from tissues with long transverse relaxation time $T_2$. Pheochromocytomas often show striking T2 hyperintensity (“light-bulb bright”) due to high water content, vascularity, and cystic change. While this finding is not entirely specific, the combination of marked T2 hyperintensity and high unenhanced CT attenuation is classically associated with pheochromocytoma.\n\nEndocrine tumor physiology and metanephrines: Catecholamine-producing tumors autonomously synthesize catecholamines, which are continuously metabolized intratumorally to metanephrines via catechol-O-methyltransferase. Plasma free metanephrines are sensitive markers of pheochromocytoma. However, borderline elevations (for example, <2–3 times the upper limit of normal) can result from non-tumor factors, including posture (seated vs supine), stress, and medications (e.g., serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants). Supine sampling after $20$–$30$ minutes of rest or $24$-hour urinary fractionated metanephrines reduces false positives. The clonidine suppression test, using an alpha-$2$ agonist, suppresses sympathetic neuronal outflow and thereby lowers neurogenic catecholamine release; tumor secretion is autonomous and will not suppress. Thus, persistent elevation of plasma normetanephrine after clonidine suggests tumor secretion; normalization suggests neurogenic elevation.\n\nGeneral surgical principles in adrenal incidentaloma evaluation emphasize: first, exclusion of hormone hypersecretion (pheochromocytoma, autonomous cortisol secretion, primary aldosteronism if hypertensive/hypokalemic); second, avoidance of invasive procedures (percutaneous biopsy) until pheochromocytoma is excluded biochemically due to risk of catecholamine crisis; third, if pheochromocytoma is confirmed, preoperative alpha-adrenergic blockade and appropriate functional imaging for localization/staging.\n\nApplying these principles to the case: The imaging phenotype (unenhanced CT $35$ HU, marked T2 hyperintensity) strongly suggests pheochromocytoma. The borderline plasma normetanephrine elevation ($1.4$ times upper limit) sampled under suboptimal conditions (seated, stressed, on a serotonin-norepinephrine reuptake inhibitor) requires repeat testing under optimal conditions. If borderline persists, clonidine suppression testing is indicated. Autonomous cortisol secretion screening with a $1$ mg overnight dexamethasone suppression test is standard in adrenal incidentaloma and should be conducted in parallel. Invasive biopsy and characterization with contrast washout CT should be deferred until pheochromocytoma is excluded. If biochemical confirmation occurs, proceed with alpha-adrenergic blockade and functional imaging such as iodine-$123$ MIBG or fluorine-$18$ fluorodopa PET.\n\nOption-by-option analysis:\n\nA. This option correctly integrates radiologic and endocrine first principles: it recognizes the high suspicion for pheochromocytoma based on CT attenuation and T2 hyperintensity; it prioritizes repeating catecholamine testing under optimal conditions (supine plasma free metanephrines or $24$-hour urinary fractionated metanephrines) to mitigate pre-analytic confounders; it appropriately uses the clonidine suppression test for persistent borderline normetanephrine elevation; it includes parallel screening for autonomous cortisol secretion with a $1$ mg overnight dexamethasone suppression test; it appropriately defers invasive procedures and contrast-based characterization until pheochromocytoma is excluded or confirmed; and it correctly plans alpha-adrenergic blockade and functional imaging (iodine-$123$ MIBG or fluorine-$18$ fluorodopa PET) if confirmed. Verdict: Correct.\n\nB. Adrenal biopsy prior to biochemical exclusion of pheochromocytoma is contraindicated due to risk of precipitating a catecholamine crisis. Moreover, deeming alpha blockade unnecessary because metanephrines are only borderline ignores the pathophysiologic autonomy of tumor secretion and the imaging phenotype. This plan violates core safety principles. Verdict: Incorrect.\n\nC. Labeling the lesion a lipid-poor adenoma and proceeding directly to contrast-enhanced adrenal washout CT without further catecholamine testing is unsafe and non-prioritized. Imaging is not decisive in the presence of a phenotype highly suspicious for pheochromocytoma, and biochemical exclusion should precede any invasive characterization. Although contrast administration itself is typically low risk, the overarching principle remains to exclude pheochromocytoma first. Verdict: Incorrect.\n\nD. Functional imaging without biochemical confirmation is not prioritized for suspected pheochromocytoma with borderline metanephrines; the first step is to optimize and confirm biochemistry. Additionally, gallium-$68$ DOTATATE targets somatostatin receptor expression, which is variably present in pheochromocytoma, and fluorine-$18$ fluorodeoxyglucose PET is nonspecific. Preferred functional imaging after biochemical confirmation includes iodine-$123$ MIBG or fluorine-$18$ fluorodopa PET. Deferring cortisol and aldosterone evaluations violates standard incidentaloma screening protocols. Verdict: Incorrect.\n\nE. Initiating beta-blockade alone risks unopposed alpha-adrenergic stimulation and potential hypertensive crisis; moreover, proceeding to surgery based solely on MRI appearance without biochemical confirmation contradicts endocrine and surgical standards. Verdict: Incorrect.\n\nTherefore, the most appropriate prioritized diagnostic plan is described in Option A.", "answer": "$$\\boxed{A}$$", "id": "4623296"}]}